Podcasts about people living with hiv

In this episode, Kathleen Page, MD, and Glenn J. Treisman, MD, PhD, discuss the interplay between addiction and HIV. Learn as they share their approaches to reframing the conversation about addiction and overcoming barriers to effective addiction care for people living with HIV.Presenters:Kathleen Page, MDProfessorInfectious DiseasesJohns Hopkins School of MedicineBaltimore, Maryland Glenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides:https://bit.ly/3TR3OVVProgram:https://bit.ly/3WB2VCO

In this episode, Tristan J. Barber, MA, MD, FRCP, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating PTSD in people with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, sharing their own experiences and approaches to thinking about PTSD, structuring appointments, and integrating care. Presenters:Tristan J. Barber, MA, MD, FRCPConsultant in HIV MedicineRoyal Free London NHS Foundation TrustHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonLondon, United KingdomGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides:https://bit.ly/4dBu929Program:https://bit.ly/3WB2VCO

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

In this thought-provoking episode, the Zvandiri 3 peers from Zimbabwe—Vimbai, Purity, and Peggy—discuss the profound effects of climate change and gender-based violence on the lives of young people living with HIV. Through their insightful conversation, they explore the unique challenges faced by this vulnerable group and highlight the urgent need for integrated solutions. Join us to hear their perspectives and learn about the resilience and strength of young people in Zimbabwe as they navigate these intersecting issues.

In this episode, Bradley N. Gaynes, MD, MPH, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating depression in people living with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, including creation of a virtual network and employment of measurement-based care.Presenters:Bradley N. Gaynes, MD, MPHRay M. Hayworth, MD and Family Distinguished ProfessorProfessor of Psychiatry and EpidemiologyDirector, Division of Global Mental HealthCo-Director, Physician Scientist Training ProgramDepartment of PsychiatryUniversity of North Carolina School of MedicineChapel Hill, North CarolinaGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides: https://bit.ly/3YgqqSOProgram: https://bit.ly/3WB2VCOTo get access to all of our new infectious disease podcast episodes, subscribe to the CCO infectious disease podcast channel on Apple Podcasts, Google Podcasts, or Spotify.  

Key Discussion Points Mental health and stigma- Strategies for mental health support and community building. Sexual and reproductive health - Focus on relationship challenges YPLWHIV face Empowerment and advocacy - Success stories of young people making a difference in their communities. Speaker - Dr. Emish Ondiek Organizations Involved Committee of African Youth Advisors (EGPAF) Paza 4 Youths

Learn more at TheCityLife.org --- Send in a voice message: https://podcasters.spotify.com/pod/show/citylifeorg/message Support this podcast: https://podcasters.spotify.com/pod/show/citylifeorg/support

 This podcast features UNAIDS India Country Director David Bridger who shares what #PutPeopleFirst means to him in lead up to 25th International AIDS Conference (AIDS 2024) to be held in Munich, Germany. He is in conversation with Shobha Shukla, CNS founder Managing Editor and Executive Director and Chairperson of Global AMR Media Alliance (GAMA).Listen to this podcast on Apple Podcasts, Amazon Music, Spotify, YouTube Music, TuneIn, Podtail, BluBrry, Himalaya, ListenNotes, American Podcasts, CastBox FM, Ivy FM, Player FM, iVoox, and other podcast streaming platforms.ThanksCNS team

This podcast features Dr Rajesh Kumar Sood, District Programme Officer, National Health Mission, Kangra, Himachal Pradesh, India. He shares what #PutPeopleFirst means to him in the lead up to the 25th International AIDS Conference (AIDS 2024).Listen to this podcast on Apple Podcasts, Amazon Music, Google Podcasts, Spotify, TuneIn, Podtail, BluBrry, Himalaya, ListenNotes, American Podcasts, CastBox FM, Ivy FM, Player FM, iVoox, and other podcast streaming platforms.ThanksCNS team

Send us a Text Message.Infant Feeding for Persons Living With and at Risk for HIV in the United States: Clinical Report. Abuogi L, Noble L, Smith C; COMMITTEE ON PEDIATRIC AND ADOLESCENT HIV; SECTION ON BREASTFEEDING.Pediatrics. 2024 May 20:e2024066843. doi: 10.1542/peds.2024-066843. Online ahead of print.PMID: 38766700 As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Angelo Baronessa from Divergent Wealth, JOY Breakfasts finance guru joined Rach and Dean as they dive into the topic of Life Insurance and people living with HIV. Insurance companies are... LEARN MORE The post Life Insurance/Income Protection & people living with HIV appeared first on JOY Breakfast.

What are the clinical and cellular effects of stigma in your patients living with HIV? Credit available for this activity expires: 3/13/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000379?ecd=bdc_podcast_libsyn_mscpedu

Despite the clear need and disproportionate risk, adolescents and young people living with HIV (AYPLHIV) are underserved in the HIV response. Peer support constitutes a crucial form of adolescent and youth-responsive service packages as part of differentiated service deliveries that can support adolescents to access,and maintain treatment. --- Send in a voice message: https://podcasters.spotify.com/pod/show/yplusglobal/message

*Send your thoughts, opinions, suggestions, and anything else you'd like to share via voicenote to 0892096423*This week's standalone interview is with drag queen, musician and HIV activist Veda. I've been admiring Veda's drag for a frankly shocking number of years now, but have been even more impressed by her work in HIV activism. Veda co-hosts Poz VIbe with fellow HIV activist Robbie Lawlor, 'a podcast for People Living With HIV, their friends, family and allies trying to create change and spread positive vibrations', and their activism has seen them travel the world. Veda's latest project is a short film about her life. Pregnant with a Drag Queen, is super camp and fun, and will air on Virgin Media One on Tuesday the 27th at 11pm, but you can also catch it on the player. I caught up with Veda this week to chat about the film, her life, her work, and what it was like to be young and gay in 90s Dublin. Hosted on Acast. See acast.com/privacy for more information.

As people living with HIV age, the risk of cardiovascular disease becomes the greatest threat to their health and quality of life. Not only does inflammation from HIV infection contribute to atherosclerotic cardiovascular disease (ASCVD), but dyslipidemia from the antivirals commonly used to treat HIV further enhances that risk. But does statin therapy reduce ASCVD risk in patients living with HIV?  That's the question that the REPRIEVE study attempted to answer. Guest Authors:  Laura Lerner, PharmD and Joseph Nardolillo, PharmD, BCACP Music by Guest Talk

In this podcast episode, Mark Brennan-Ing, PhD, and Nina I. Martinez discuss mental health challenges in people living with HIV and much-needed strategies to overcome these challenges to optimize engagement in HIV care, including:The increased rates of mental health disorders and substance use among people living with HIVHow mental health disorders contribute to challenges with adherence to HIV treatment and engagement in careHow social isolation and stigma can affect outcomes despite access to HIV care and ARTThe importance of mental health screenings as part of HIV careIntegrating mental health services into HIV care as a strategy to overcome mental health challenges being a barrier to carePresenter:Mark Brennan-Ing, PhDDirector of Research and EvaluationBrookdale Center for Healthy AgingHunter CollegeThe City University of New YorkNew York, New YorkNina I. MartinezPublic Health ConsultantLink to full program: https://bit.ly/3TqVnl1

In this podcast episode, Babafemi Taiwo, MBBS, and Vincent Crisostomo discuss the evolving treatment landscape for aging people living with HIV, encompassing the clinical and external resources necessary to support physical and psychosocial health. The topics discussed include:• Mindful prescribing and understanding the impact an HIV diagnosis can have on one's mental health, including social isolation• How to address patients' needs and establish a trusting relationship within the confines of a 15-minute clinic visit• How research is helping healthcare professionals better understand this clinical situation and discover opportunities to equalize metrics• The critical role of social workers and community organizations in patients' overall care• Accessing federal HIV disability resources• Informed patient–provider discussion and counseling on medical decision-making regarding ART• How healthcare professionals can move toward clinical practice that leaves no one behindPresenter:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChiefDivision of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisVincent CrisostomoDirectorAging ServicesSan Francisco AIDS FoundationSan Francisco, CaliforniaLink to full program:https://bit.ly/3TqVnl1 

Which factors influence cardiometabolic disease in people living with HIV and how can you properly manage it? Credit available for this activity expires: 12/11/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999145?ecd=bdc_podcast_libsyn_mscpedu

Every year on 1st December, we mark World AIDS Day to show solidarity in the fight against HIV and AIDS, and to remember those who have sadly lost their lives. Since the start of the global AIDS epidemic in the 1980s, researchers have made enormous progress towards preventing HIV transmission, and treating those who are living with HIV so that the virus remains suppressed. But while there have been marked improvements for adults, treatment coverage in children and adolescents is lagging behind. In the second of our World AIDS Day episodes, we highlight the important role that young people living with HIV play in research, by shaping clinical trials to better serve the needs of their community. This episode features Lungile Jafta, who works closely with young people through Penta's youth engagement programmes, and Gugu, a former Youth Trials Board member from South Africa who is living with HIV. For more information and to access the transcript: https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/december/trial-talk-podcast-releases-new-episodes-for-world-aids-day/ For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Do you know the characteristics of cognitive disorders in people who are HIV positive? Do you know the pathogenesis of this neurocognitive decline?    Credit available for this activity expires: 10/25/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/997643?ecd=bdc_podcast_libsyn_mscpedu

Obtain Credit   |  View Activity Information…

Daily weight fluctuation is normal and comes down to what and when we eat, drink, exercise, and even sleep. For most of us, shedding the extra few pounds and or replacing fat with muscle seems like a never-ending quest. But for people living with chronic conditions, including HIV, significant weight gain is an important considerations that sometimes requires consulting with a clinician to get it right. On this episode of HIV Connect we will explore the ins and outs of achieving and sustaining a weight that promotes our overall health and well-being.

In this episode, Nikos Dedes, Jeff Taylor, and Bernadette Sharp—people living with HIV—discuss how switching to long-acting ART has affected their quality of life. They are joined by 2 healthcare professionals—Iskandar Azwa,MBChB, MRCP, and Beng Eu, MBBS—who provide insights on how they assess and document health-related quality of life for their patients. The discussion focuses on personal experiences with how LA ART has improved health-related quality of life, including:Avoidance of drug–drug interactionsImproved confidentiality Decreased stigmaPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://bit.ly/488WwT7Link to full program: bit.ly/3EwEnRJ

In this episode, Iskandar Azwa, MBChB, MRCP; Nikos Dedes; Beng Eu, MBBS; Bernadette Sharp; and Jeff Taylor discuss challenges and opportunities with long-acting ART implementation, including:Personal experiences with receiving LA ART Views on long-acting ART in the development pipelinePerspectives on self-administration of LA ARTPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic  Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://clinicaloptions.com/CE-CME/infectious-disease/slides-fourth-90-and-la-art/17553-25368  Link to full program: https://bit.ly/3EwEnRJ

In this episode of Africa Science Focus, we speak to Maureen Akolo, a nurse and public health specialist in Kenya who supports communities at risk of HIV/AIDS, including sex workers and drug addicts. She works to create awareness about HIV/AIDS and encourage and educate people about life-saving treatments such as anti-retroviral drugs.Our reporter, Michael Kaloki, also hears from a patient living with the disease about how she accepted her diagnosis and is living a healthy life thanks to Akolo's mentorship.-------------------------------------------------This project was funded by the European Journalism Centre, through the Solutions Journalism Accelerator. The fund is supported by the Bill & Melinda Gates Foundation.Do you have any comments, questions or feedback about our podcast episodes? Let us know at podcast@scidev.net Africa Science Focus is produced by SciDev.Net and distributed in association with your local radio station.Do you have any comments, questions or feedback about our podcast episodes? Let us know at podcast@scidev.net

Catherine Godfrey is the senior technical advisor for adult treatment at the U.S. President's Emergency Plan for AIDS Relief. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. C. Godfrey and J. Nkengasong. Prioritizing Mental Health in the HIV/AIDS Response in Africa. N Engl J Med 2023;389:581-583.

In this JCO Article Insights episode, Davide Soldato interviews Dr. Naqash  from University of Oklahoma. Dr. Naqash provides insight into the original article published in the July JCO issue: “Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium”. The interview offers a deep dive into the manuscript results on efficacy and safety of Immune Checkpoint Inhibitors in this specific population and offers insights on future research direction in this space. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Davide Soldato: Welcome to this JCO Article Insights episode for the July issues of JCO. This is Davide Soldato and today I will have the pleasure of interviewing Dr. Abdul Rafeh Naqash, the author of the manuscript titled "Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer: A Real World Report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International Consortium."  Dr. Naqash is an Assistant Professor of Hematology-Oncology at the University of Oklahoma and a Medical Oncologist working at the Stephenson Cancer Center. His research interests revolve around early-phase clinical trials in solid tumors, lung cancer, and the study of immunotherapy, biomarkers, and resistance.  Welcome, Dr. Naqash, and thank you for accepting our invitation today. Dr. Abdul Rafeh Naqash: Dr. Soldato, thanks so much for having me. I'm really excited to discuss this article with you today. Davide Soldato: So I just wanted to go a little bit over the manuscript with you. So basically, this is a retrospective multicenter study that was conducted across the US, Europe, and Australia by the CATCH-IT Consortium. And so the aim of the study was really to investigate the safety and the activity of immune checkpoint inhibitors among patients diagnosed with cancer and also living with HIV. The article examined two different cohorts, and I just wanted to start with a brief explanation of how the two cohorts were built so that our readers can get a little bit of understanding of what you did then. Dr. Abdul Rafeh Naqash: Sure. Before I take a deep dive into the cohorts, Dr. Soldato, I would definitely like to mention the premise and the background for this paper as to why we did what we did. And one of the primary reasons was that people living with HIV, historically, there have been very limited number of trials that have included these individuals. So it becomes a very important question from a disparity standpoint. And most often we end up, in the real world setting, we end up extrapolating data from clinical trials, but not necessarily know what is the outcome of these individuals in the real world setting.  So there have been some very important studies in the last three years or so in people with HIV as far as clinical trials with checkpoint inhibitors go, but most of those trials have been limited by the number of patients, number of people that have been part of those trials. So we wanted to understand it from a broad perspective, whether it is from a broad geographic perspective or from a heterogeneous patient population perspective, which is why we built this consortium called the CATCH-IT Consortium, which basically stands for Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International Consortium. And this required a lot of effort from a lot of different centers, including those in the US, Europe, and Australia, as you mentioned. And then we ended up having data worth around 400 plus patients, close to 400 patients or so. And then we wanted to look at obviously outcomes, whether it's related to a certain tumor such as lung cancer, which we did in this case, or a pan tumor assessment of toxicities and safeties.  So, to your question, the cohorts that we basically had, we had close to approximately 390 patients that we included in the safety analysis. So first we looked at the safety analysis, which was the entire cohort, and then out of those we excluded around 12 patients or so. Those were patients that were treated in the adjuvant setting. So in the metastatic advanced setting, we had close to 378 individuals that we assessed clinical outcomes for. So, response rates, progression-free survival, and overall survival. And then as far as a separate cohort, we looked at non-small cell lung cancer, which was the most commonly represented tumor type, with approximately 111 patients that had non-small cell lung cancer. We did exclude a certain proportion of those that were earlier stage, stage III.  So in the stage IV, basically we ended up matching in this separate cohort, around 60 odd patients or so of non-small cell lung cancer to 110 stage four, non-small cell lung cancers. So basically it was a one-to-two matching and we chose the same site. So if a site had, let's say, two people with HIV and lung cancer treatment checkpoint, we tried to match it to approximately four to five patients from the same site and we used some variables for matching so that we had some level of homogeneity between the HIV patient population and the non-HIV positive lung cancer individuals. So that's basically cohort A was around 370-something patients, tumor agnostic advanced metastatic setting. Cohort B was lung cancer individuals matched to non-HIV positive lung cancer treatment checkpoint inhibitors. Davide Soldato: Thank you very much. That was very clear. Just to go back to what you were saying before because I think that this is very interesting. You mentioned that patients living with HIV were mostly excluded from clinical trials and in the few that included them, there were some restrictive criteria in terms for example of CD4-positive cells in the blood. And so I was wondering if when you included the patients inside of this cohort, you also had this type of exclusion criteria or you chose a broader population to make the results more generalizable and applicable in clinical practice.  Dr. Abdul Rafeh Naqash: Right, a very important question. Thank you, Dr. Soldato. So yes, previous clinical trials have had some level of restrictions as far as the inclusion of these individuals, but in our study, this was a real-world study, basically, patients whoever presents to the clinic with a history of HIV, they were all included. So we did not restrict it to certain CD4 counts or viral loads because the important thing was we wanted to understand the ground situation of how these individuals do, irrespective of some of these limitations. As far as what we identified as baseline CD counts or HIV viral load positivity, we took three months before immune checkpoint initiation as a cut off so obviously there's a limitation there. We didn't have results of these CD4, CD at a viral load assessments done like the day of or the week before in some patients. So we took three months and we included individuals that had received at least one or more dose of immune checkpoint therapy between January of 2015 to October of 2021, which was our database lock.  And then obviously the regimens included immune checkpoint anti-PD1, PD-L1 monotherapy, or in combination with other anticancer agents including anti-CTLA-4 or chemotherapies targets, which is important to point out here. So the trials that have been mostly done in this space are single-agent checkpoint inhibitors or anti-PD1 with anti-CTLA-4. There's not much data for immune checkpoint inhibition combined with other agents such as targeted therapies, chemotherapies. So we had some of that data in this cohort, which kind of made it interesting. Davide Soldato: Yeah, I think that it's very interesting and it's very wise to choose very broad eligibility criteria for these type of studies because it really answered to the question that we identified and that we spoke about in the beginning.  So going back to the results, you said that the cohort A, so the one that included all the patients, irrespectively of the type of tumor that was diagnosed, it was mainly for evaluating what was the safety of immune checkpoint inhibitors in patients living with HIV and with a concurrent cancer diagnosis. So I was wondering if in this cohort you identified some differences compared to historic data in terms of, for example, incidence of grade three or higher toxicities or incidence of immune-related adverse events in general, and if maybe there was some adverse events that was very characteristic or particular in this cohort. Dr. Abdul Rafeh Naqash: So immune-adverse events is a very interesting question not only from this cohort but in general because it overlaps with this question of autoimmunity and cross T cell cross reactivity. And this is a unique patient population where we have the ability, although not fully but to some extent, to look at the role for CD counts and also look for patterns of adverse events.  To answer your first part of the question, we didn't see any significant differences for the types of adverse events. We did see the incident was a little lower than what you would expect in the real-world setting for non-HIV individuals. Whether that has something to do with how the immune system is constructed in these individuals, nobody knows. We did look at CD4 and CD8 counts. As far as absolute CD4 counts, about 200 or below 200, we didn't see a difference as far as the cumulative incidence for immune checkpoint inhibitor-related adverse events. When we did a ratio of CD4 to CD8 of greater than 0.4 and compared it to less than 0.4, we did see that at around 24 weeks, there was a difference in terms of the cumulative incidence for adverse events. It was around 10% versus 26% when we use that cut-off of 0.4, suggesting that there might be some role of how the peripheral immune system results in the related adverse events in these individuals, but it's a very important question.  I think there are ongoing evaluations that are being done from other prospective studies that had collected blood samples in these individuals. But generally, we saw the same range of adverse events, diarrhea, colitis, pneumonitis, hepatitis. We did have a few patients who had  a history of opportunistic infections, but we didn't see any significant reactivation there which was part of the safety assessment in our analysis.    Davide Soldato: So basically, because I think that in HIV patients, even if those included in the study were almost all were on antiretroviral therapy, but you didn't observe any opportunistic infection that developed during the course of immunotherapy. Dr. Abdul Rafeh Naqash: You're absolutely right, we did not. In fact, we are trying to look at that in a different setting, in a different cohort because there have been some data on mycobacterial reactivation in individuals in general, not just HIV, but in our cohort of 400 odd patients, we did not see any new opportunistic infections. Davide Soldato: I think that one aspect that pops into my mind right now is also that we have kind of some data regarding also possible HPV reactivation in these types of patients treated with immune checkpoint inhibitors. So maybe that could be also something that you would be interested to look at in the future, I imagine.  Dr. Abdul Rafeh Naqash: Yes, we are planning to look at HPV-driven cancers actually for starters, anal and head and neck. We are also looking at hepatitis B-related HCC in a separate ongoing cohort. So there are definitely subsequent steps that we are currently involved in as far as viral-driven cancers and concurrent HIV is concerned. Davide Soldato: Thank you. I think that's very interesting. And I was wondering, you mentioned in the beginning that this patient clearly they have some degree of immune dysregulation or at least some type of dysfunction in terms of immune presentation and immune activation. So I think that one of the concerns or one of the worries of using immune checkpoint inhibitors in this population could also be that the efficacy that we see in patients that do not have HIV could be lower. Could you comment on this if you found any differences both in the cohort including all cancer, but also in the cohort B, that I think you had the strategic idea of pairing these patients living with HIV with patients that were not living with HIV. So I think that this brings very important data to the space. Dr. Abdul Rafeh Naqash: Yes, we tried to look at this one from a tumor-agnostic perspective and a tumor-specific perspective. So the tumor agnostic perspective was looking at a different set of cancers which included skin cancer, melanoma, lung cancer, non-Hodgkin's lymphoma, small cell head and neck, and a couple of other cancers. And one of the things we noticed was that there was a trend, so there was differential efficacy as far as the cancer type is concerned. So for example, skin, Hodgkin's lymphoma, Kaposi sarcoma, melanoma had the highest response rates, somewhere in the range of 60s to 40s. On the other hand, viral-driven cancers such as anal cancer, HCC, head and neck actually had very low response rates, less than 15% or so. So that begs the question of what is going on and we don't necessarily know, which is why we are trying to concentrate on the viral-driven cancers first. Because as you know, melanoma, Kaposi's do have historically shown better responses to checkpoint inhibitors.   Now do we know if when we compare these responses or survival to non-HIV individuals in clinical trials, are the outcomes similar? I would say in some of the tumor types the outcomes were somewhat inferior and in some of the tumor types the outcomes were somewhat similar. So for example, lung, we did compare non-small cell lung cancer. As I mentioned, we had two cohorts, we matched it to a non-HIV cohort and there we looked at progression-free survival and overall survival. And again the caveat is that this is a retrospectively matched cohort, this is not a prospectively matched cohort. So these are individuals that are not matched for each and every variable. They're matched for certain top three or four variables as much as we could accommodate. And based on that we didn't see a difference in the progression-free survival and the overall survival when we did an assessment.  In fact, we looked at it at a 42 month period where we looked at the restricted median survival time and it was not different, was around 17.8% for people with HIV and 18.4% for people without HIV as far as progression-free survival, and around 42% and 41% overall survival at the two-year mark. So basically there is not much significant difference which reiterates the fact that in the right setting, these individuals could be safely treated with immune checkpoint inhibition and could perhaps have similar outcomes. Maybe not in all tumor types, but in some tumor types. But at the end of the day, and we mentioned this in our manuscript also in subsequent work that we are trying to do, we have emphasized on the fact that it has to be a multidisciplinary discussion between the patient, the physician, the medical oncologist, the treating oncologist, and the infectious disease person. Because these individuals have a lot of complicated aspects because of the underlying HIV and taking that into perspective and then assessing risk-benefit is an important discussion.  So the goal of this work was not to establish that immune checkpoint inhibitors are absolutely beneficial or absolutely safe. The goal was more to create awareness that people in the real-world setting actually can benefit, which the next step would be to have more trials and perhaps modify inclusion criteria in clinical trials so that you can have a more inclusive approach, including these individuals.  Davide Soldato: Coming back to the multidisciplinary approach because I think that this is very interesting and should be really implemented when we have this type of patient. From the data that you collected, did you add any indication that maybe this patient treated in the real-world setting were not managed in such a multidisciplinary way? Dr. Abdul Rafeh Naqash: The easiest way to point that out is that most of these people or many of these individuals did not have HIV viral loads or CD4 counts done before treatment initiation. And that's an indirect surrogate for telling you that these are things that should have been thought of, but were not thought of if the individual taking care of these people either did not have expertise as far as HIV is concerned or did not have a colleague on the infectious disease side who was actively managing these people.  So that's an important indirect way where we kind of got a sense that there has to be more awareness about multidisciplinary care. And especially the immune adverse event situation in these individuals can get complicated because of the way their immune system is constructed and having that multidisciplinary care is very important. We didn't specifically collect data on what teams or what subspecialists were involved in each individual's care, but I think that would be an important assessment for maybe a future quality improvement project to look at why or how some of those things were not done so that it can lead to future improvements. Davide Soldato: So, just expanding on that, you said that you didn't have much data in terms of CD4 cells or in terms of viral load. But for what you had inside of your cohort, did you see any modification of these parameters that we know that are very important in patients living with HIV under immune checkpoint inhibitors therapy? Dr. Abdul Rafeh Naqash: Again, a very important immunological question, I think as far as what we saw- so we had close to around 74, 75 individuals that had CD4 T cell counts available. And we didn't see differences between baseline and post-immune checkpoint therapy changes in CD4 counts. Similarly, we didn't see a difference as far as HIV viral load and we had HIV viral loads present in around 107 individuals and we didn't see a difference. Now, again, 30% of our cohort was CD4 count less than 200, and 70% was CD4 count more than 200, , which is again, important to highlight because many trials don't take individuals with the CD4 count less than 200. But in general, we did not see a difference in this pre and post-assessment both for viral load and both for CD4 count. Now trials in this space have ongoing assessments that they are doing. The AIDS Malignancy Consortium does have a trial looking at changes in CD4/CD8 counts or viral loads. In fact, the CITN trial which is a pembrolizumab trial published a couple of years back did have an assessment done as far as CD4 counts and viral loads are concerned. And I think they did see a slight increase in the CD4 counts and there are some aspects about how the immune system may change with an immune checkpoint inhibitor. But I think the strength of the data is not that much, and I think we probably need more patient samples to assess why or how some of that could change or what implications it would have for patients.  Now, there is another concept of HIV viral latency removal that some of the listeners might have heard of, especially in the HIV setting, where you were given an immune checkpoint inhibitor and it can lead to reversal or reduction of the HIV reservoir, which can somehow impact the CD4 counts, and also lead to elimination of the viruses through CD8. But again, that's a more complicated assessment and we didn't have data for it.   Davide Soldato: Thank you very much. That was very interesting also for future perspectives in this topic.  I just wanted to ask you if the idea for the research came more from ensuring equity in terms of care delivery for patients living with HIV or if it was more also to investigate the immunological components that we discussed just as far or a good mix of the two. Dr. Abdul Rafeh Naqash: I think the idea actually stemmed from this individual who's the first author, Dr. Talal El Zarif and co-first author Dr. Amin Nasser from Dana-Farber, reached out a year and a half back and they wanted to look at outcomes from an HIV standpoint and see what the real world setting is. And the goal was they would have their data and we would have our data and we would eventually collect the data together or combine the data together. But then after some conversations, we started looking at the available data, the available literature, saw that there was a decent gap in what we know. And I know there are some brilliant groups in the HIV space, especially at the NCI. In fact, Dr. Kate Lurain and Dr. Ramaswami are good collaborators of ours and they worked in this space and are currently developing trials in this space. But it just did seem like this would be a more interesting approach of answering a real-world question and then also looking at the disparities of it because as an early-phase drug development trialist, I still see a lot of trials, in fact, majority of the trials, say people with HIV or history of HIV are excluded.  Now, the NCI has made important efforts in that space of including those individuals, but I think we still have some ways to go. So basically the idea came from two trainees who were extremely enthusiastic and wanted to pursue this. And I, obviously, seeing their level of enthusiasm and excitement, I was excited too. And then importantly, if you look at the paper, we have a bunch of authors, we have close to 79, 80 authors on that paper. And the primary reason was that each center contributed in certain ways, including patients' data and then expertise. And this ended up being a huge community effort from the oncology community, where everybody's individual effort led to something like this coming to fruition.  So it was a multitude of different aspects, but yes, it all started with a question of how these individuals do and the current data where they're missing gaps, and we wanted to sort of supplement those gaps and provide insights using this important real-world data set. Davide Soldato: Thank you very much for the insight on how the idea came to be.  Is there anything else you would like to add or to summarize for our listeners? Dr. Abdul Rafeh Naqash: Well, first of all, I appreciate the opportunity to discuss our paper here. I would like to thank you and of course the JCO staff for organizing this, and also the JCO Journal for giving us the opportunity to publish this important work. Some of the things that we would like to highlight as outcomes from this paper, as we sort of discussed, but to summarize those: we saw that we didn't have any significant safety concerns, obviously. We saw that some patients in certain tumor types do benefit, similar to what you might expect in a non-HIV setting in the real world as well.  And of course, this was the largest real-world data set of people with HIV and cancer. And we have ongoing efforts in different directions, as I mentioned to you. And we are more than happy to collaborate with anybody who has good ideas because this is a community-level data set. It was created for the community, by the community, and the goal is to utilize this data set. So if there is a listener out there who's interested in collaborating, who has an idea, we're more than happy to share the data set in the right setting. And then hopefully, everybody has the opportunity to lead different efforts in the space. Davide Soldato: Thank you again for being with us today, Dr. Naqash. To hear more from Dr. Naqash, please check out ASCO's JCO Precision Oncology Conversation Podcast.  So this is Davide Soldato. In this episode of JCO Article Insights, we discussed the results of the manuscript titled, “Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer: A Real World Report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International Consortium.” Thank you for your attention and stay tuned for the next episode.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

This month, we're going to explore a significant set of recent changes to U.S. HIV clinical guidelines. These changes are momentous in and of themselves, but they also reveal an important ongoing shift in how we fundamentally approach the clinician-patient relationship, especially when it comes to pregnant and infant-feeding people who are living with HIV.     Joining us for this conversation are two people who have been deeply involved in these guideline changes: Lealah Pollock, M.D., and Ciarra (Ci Ci) Covin. Dr. Pollock is an associate professor of Family Community Medicine at the University of California-San Francisco School of Medicine, and she's a member of the expert panel that recently updated the guidelines we discuss. Ci Ci Covin is an HIV advocate and mother of two who has been living with HIV since 2008, and she's a program manager at The Well Project, a nonprofit organization devoted to informing and supporting women who are living with, or vulnerable to, HIV.     Read the transcript: https://www.thebodypro.com/article/future-hiv-care-podcast-15-breastfeeding-chestfeeding     This month's episode is hosted by Myles Helfand. Our executive producer is Myles Helfand; our project manager is Alina Mogollon-Volk; our audio producers/engineers are Alex Portaluppi and Lucy Mueller; and our series editors are Maria Elena Perez and Juan Michael Porter II. Audio for this episode was edited by Kimberly Buikema.

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Andrew Ustianowski, MBBS, FRCP, PhD - What's Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Ciarra “Ci Ci” Covin is a mother, advocate, and lover of all human beings. Diagnosed with HIV at the age of 20, Ci Ci has curated a life of HIV and mental advocacy through both her lived experience and education. Ci Ci is program manager at The Well Project, past Ambassador for the CDC's Let's Stop HIV Together Campaign, and Owner of Healing Is Voluntary, LLC. In these roles, Ci Ci has been able to connect with other leaders from around the world to further the mission of destigmatizing HIV and providing a community for women who are living with HIV. Learn more about HIV and the work at The Well Project here and follow them on Twitter.  Check out Ci Ci's A Girl Like Me series.In this podcast we talk about the persistence of HIV stigma in society and how it affects self-stigma and self-acceptance, advances with U=U, breastfeeding and HIV, and how people living with HIV are still human, with the same desires that might just look a little different. Ci Ci shares simple and powerful ways we can all challenge HIV stigma.Episode hosted by Dr. Carmen Logie. Supported by funding from the Canada Foundation for Innovation and Canada Research Chairs program. Original music and podcast produced by Jupiter Productions, who have various production services available to support your podcast needs.

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

Can you identify the drivers and risk factors of suboptimal treatment adherence for people living with HIV? Learn from expert faculty how best to support patients. Credit available for this activity expires: 12/05/23 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/984441?src=mkm_podcast_addon_984441

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​, discusses strategies for and importance of HIV care engagement and reengagement for those who have fallen out of care. Her overview includes:WHO Global Health Strategy on HIVLongitudinal HIV care trajectoriesPromotion of successful care and antiretroviral therapy (ART) adherenceDifferentiated service deliveryImproving care and ART adherence in high-risk groupsPatient perspectives on ART persistence Presenter:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​Director​Desmond Tutu HIV Centre​Past President​International AIDS Society​Faculty of Health Sciences​University of Cape TownCape Town, South Africa​Panelists:Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS-Infectious Diseases Medical Centre​DirectorChennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaChloe Orkin, MBChB, FRCP, MD​Professor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Babafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern University Feinberg School of Medicine​Chicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3dSNoumLink to full program:https://bit.ly/3AE2AV1

In this episode, Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, discusses the importance of linking people to care after a positive HIV diagnosis. His overview includes:HIV care continuumFactors that delay linkage to careOrganized strategies to improve linkage to care for people with HIVInterventions that may improve linkage to care for people with HIVPatient perspective on how to engage patients in their HIV care Presenter:Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaPanelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​Director​Desmond Tutu HIV Centre​Past President​International AIDS Society​Faculty of Health Sciences​University of Cape TownCape Town, South Africa​Chloe Orkin, MBChB, FRCP, MD​Professor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3PJ4iJ8Link to full program:https://bit.ly/3AE2AV1

In this episode, Chloe Orkin, MBChB, FRCP, MD​, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:Recommendations for rapid ARTFirst-line ART regimens for treatment-naive people with HIVIMEA 055 FAST studySTAT studyDIAMOND studyAntiretroviral resistance mutationsPatient perspectives on the importance of rapid ART initiationPresenter:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Panelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​DirectorDesmond Tutu HIV Centre​Past PresidentInternational AIDS Society​Faculty of Health SciencesUniversity of Cape TownCape Town, South Africa​Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaBabafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern UniversityFeinberg School of Medicine​Chicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3dSNoumLink to full program:https://bit.ly/3AE2AV1

In this episode, Babafemi Taiwo, MBBS, discusses strategies for reaching people with HIV who are not yet diagnosed. His overview includes:HIV diagnosis by global regionDisparities in serostatus awarenessPatient perspective on importance of HIV testingBarriers to HIV diagnosisComplications from late HIV diagnosisStrategies to improve rates of HIV testingPresenter:Babafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern UniversityFeinberg School of Medicine​Chicago, IllinoisPanelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDDirectorDesmond Tutu HIV Centre​Past PresidentInternational AIDS Society​Faculty of Health SciencesUniversity of Cape TownCape Town, South Africa​Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3PJRthDLink to full program:https://bit.ly/3AE2AV1

Drs Michael Saag and Judith Currier discuss options for long-acting HIV therapies, minimizing patient interactions with the healthcare system, and honoring patient preferences. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963242). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources AIDS Clinical Trials Group (ACTG) https://www.niaid.nih.gov/research/aids-clinical-trials-group Cabotegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156 Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563641/ Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/interactions-between-integrase-inhibitors-and-non-nucleoside Initiation of Long-acting Cabotegravir Plus Rilpivirine as Direct-to-Injection or With an Oral Lead-in in Adults With HIV-1 Infection: Week 124 Results of the Open-Label Phase 3 FLAIR Study https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00184-3/fulltext Lenacapavir (Pending FDA Approval) https://reference.medscape.com/drug/lenacapavir-4000240 Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir https://www.gilead.com/news-and-press/company-statements/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir Drug Database: Lenacapavir https://clinicalinfo.hiv.gov/en/drugs/lenacapavir/health-professional Doravirine Prescribing Information https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults https://actgnetwork.org/studies/actg-a5357-a-study-of-long-acting-cabotegravir-plus-vrc01ls-to-maintain-viral-suppression-in-hiv-1-infected-adults/ Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV https://clinicaltrials.gov/ct2/show/NCT04334915?term=ACTG+5363&draw=2&rank=1 Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189692/ Evusheld (Formerly AZD7442) Long-acting antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19 https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html

Today, in episode 575, our expert Infectious Disease Doctor and Community Health Specialist discuss what you need to know about Public Health. We talk about the historical challenge of vaccinating children, as well as how people living with HIV are more likely to get a breakthrough infection of COVID. As always, join us for all the Public Health information you need, explained clearly by our health experts. Website: NoiseFilter - Complex health topics explained simply (noisefiltershow.com) Animations: NoiseFilter - YouTube Instagram: NoiseFilter (@noisefiltershow) • Instagram photos and videos Facebook: NoiseFilter Show | Facebook TikTok: https://www.tiktok.com/@noisefiltershow --- Send in a voice message: https://anchor.fm/noisefilter/message

Listen to another episode of CNS #endAIDS Dialogues featuring Dr N Kumarasamy, who has been involved with HIV medical care and advancing HIV science since 1994, is Director of Infectious Diseases Medical Centre Voluntary Health Services Hospital, and Secretary General of AIDS Society of India (ASI). He is in conversation with CNS Managing Editor Shobha Shukla at 13th National Conference of AIDS Society of India (13th ASICON). He is also the Scientific Co-Chair of 13th ASICON.Listen to this podcast on Apple Podcasts, Amazon Music, Google Podcasts, Spotify, Stitcher, TuneIn, aCast, Podtail, BluBrry, Himalaya, ListenNotes, American Podcasts, CastBox FM, Ivy FM, and other podcast streaming platforms.

Die Ukraine hat die zweitgrößte Zahl an Menschen mit HIV in Europa. Valeria Rachynska von 100% Life, der größten NGO zur Hilfe von Menschen mit HIV in der Ukraine hat mit Gersin Livia Paya über die aktuelle Notlage, den fehlenden Transport von Medikamenten und ihre Situation als eine von geschätzten 250.000 HIV positiven Menschen in der Ukraine gesprochen.

A poem of hope and encouragement dedicated to people living with HIV/AIDs.

Why do some patients experience low CD4 T-cell counts? Join our expert faculty to find out. Credit available for this activity expires: 1/4/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/965495?src=mkm_podcast_addon_965495

Despite years of progress, people living with HIV in Malaysia continue to be stigmatised by society, making it difficult for many to continue receiving medical and social support to lead a quality life. But many grassroots organisations are out there to provide that support and to change mindsets one at a time, and one of those organisations is Komuniti Cakna Terengganu. The co-founder of KCT, Dr Mahani Nordin, was recently awarded the Sunway-Malaysian AIDS Foundation Tun Dr Siti Hasmah Award 2021, as recognition of the work that she's done with the HIV community in Terengganu. She joins us to share more about the work that KCT does, and how we can do better to help people living with HIV across the country.Image credit: Shutterstock

Social ills against people living with HIV

Guest: Prof Wendy  Burgers |  Associate Professor in the Division of Medical Virology and a full member  at Institute of infectious Disease and Molecular Medicine at UCT Africa is joined by Wendy Burgers, Associate Professor in the Division of Medical Virology and a full member of the Institute of Infectious Disease and Molecular Medicine, the University of Cape Town to talk about how Covid-19 patients living with HIV and cancer may contribute to new COVID-19 variants emerging. See omnystudio.com/listener for privacy information.

This is World AIDS Day 2021. Stigma reduction has become an increasingly important part of the NSW HIV strategy. Though what is it? What can we do about it? To discuss the detrimental effects of stigma and the research, I am joined by Dr Timothy Broady who is a senior research fellow from UNSW's Centre for Social Research in Health. To talk about his lived experience of HIV related stigma, I'm joined by a member of Positive Life NSW's Positive Speaker's Bureau, Freddy Cole. To stay up to date with the latest information in sexual health, you can follow us on social media: https://www.facebook.com/SydneySHC https://twitter.com/SydneySHC https://www.linkedin.com/company/sydney-sexual-health-centre Host: Thomas Munro Guests: Dr Timothy Broady, UNSW. Freddy Cole, Positive Speaker's Bureau.

How does inflammation impact people living with HIV? Join the experts to find out. Credit available for this activity expires: 11/23/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/963221?src=mkm_podcast_addon_963221

Prof José Miro (University of Barcelona) and Dr Juliana Reyes (Public Health Agency of Catalonia) speak to Editor-in-Chief Peter Hayward about SARS-CoV-2 and COVID-19 in people living with HIV.Read the full article:https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00240-X/fulltext

In this podcast we hear about the new SSHC co-morbidity screening clinic for people living with HIV. It is designed to work collaboratively with general practice to improve health outcomes. Listen to find out more about the role of nurses in the clinic and how it operates. To stay up to date with the latest information in sexual health, you can follow us on social media: www.facebook.com/SydneySHC twitter.com/SydneySHC www.linkedin.com/company/sydney-s…al-health-centre Host: Thomas Munro Guests: Dr. Rick Varma, Clinical Services Manager, SSHC Rebecca Houghton, Nurse Unit Manager, SSHC

According to the Network of People Living with HIV/AIDS in Nigeria (NEPWHAN), 21 percent of people between the ages of 18 and 44 living with HIV in Nigeria experience stigma and discrimination. Why do people still discriminate against people living with HIV and Aids in Nigeria?On Nigeria Daily, we talk about the level of discrimination against people living with HIV and Aids and what is being done about it. 

Optimizing Care for People Living with HIV: Beyond Typical Risk Factors for Weight Gain | PTCE Connect Educational Objectives Describe recent data surrounding weight gain among people living with HIV (PLWH) who are on antiretroviral therapy Recognize the role of the pharmacist in the care of PLWH Continuing the Conversation – Individualizing the Management of HIV: A Focus on Weight Gain Introduction of faculty, affiliations, and disclosures Dr. David Koren, PharmD, MPH, BCPS, AAHIVP, Clinical Pharmacist Specialist in Infectious Diseases at the Temple University Health System, Philadelphia, Pennsylvania Dr. Koren has the following relevant financial relationships with commercial interests to disclose: Advisory Boards: Gilead, Thera, and ViiV Independent consulting: AbbVie and Thera Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 credit hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Access PTCE here: https://www.pharmacytimes.org/on-demand/continuing-the-conversation-individualizing-the-management-of-hiv-a-focus-on-weight-gain See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Optimizing Care for People Living with HIV: Beyond Typical Risk Factors for Weight Gain | PTCE Connect Educational Objectives Describe recent data surrounding weight gain among people living with HIV (PLWH) who are on antiretroviral therapy Recognize the role of the pharmacist in the care of PLWH Continuing the Conversation – Individualizing the Management of HIV: A Focus on Weight Gain Introduction of faculty, affiliations, and disclosures Dr. David Koren, PharmD, MPH, BCPS, AAHIVP, Clinical Pharmacist Specialist in Infectious Diseases at the Temple University Health System, Philadelphia, Pennsylvania Dr. Koren has the following relevant financial relationships with commercial interests to disclose: Advisory Boards: Gilead, Thera, and ViiV Independent consulting: AbbVie and Thera Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 credit hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Access PTCE here: https://www.pharmacytimes.org/on-demand/continuing-the-conversation-individualizing-the-management-of-hiv-a-focus-on-weight-gain See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Optimizing Care for People Living with HIV: Beyond Typical Risk Factors for Weight Gain | PTCE Connect Educational Objectives Describe recent data surrounding weight gain among people living with HIV (PLWH) who are on antiretroviral therapy Recognize the role of the pharmacist in the care of PLWH Continuing the Conversation – Individualizing the Management of HIV: A Focus on Weight Gain Introduction of faculty, affiliations, and disclosures Dr. David Koren, PharmD, MPH, BCPS, AAHIVP, Clinical Pharmacist Specialist in Infectious Diseases at the Temple University Health System, Philadelphia, Pennsylvania Dr. Koren has the following relevant financial relationships with commercial interests to disclose: Advisory Boards: Gilead, Thera, and ViiV Independent consulting: AbbVie and Thera Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 credit hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Access PTCE here: https://www.pharmacytimes.org/on-demand/continuing-the-conversation-individualizing-the-management-of-hiv-a-focus-on-weight-gain See omnystudio.com/listener for privacy information.

Jeff Berry and Derrick Mapp are both long-time survivors of HIV. They are advocates in their community and work for HIV organizations to help other persons living with HIV find normalcy in their lives. Their mission is to reduce the stigma of HIV. In this week's episode, you'll learn about Shanti Project and The Reunion Project, and how these organizations support and bring people together in the local community for deeper connection and love.    TAKEAWAYS: [1:55] Jeff Berry shares that he has been living with HIV since 1989. He's been working in Chicago for different HIV awareness organizations throughout his career. [2:35] Derrick Map introduces himself as a long-time survivor living with HIV since 1995. He's currently living in San Francisco and working for Shanti Project, an HIV organization. [3:25] Shanti project is a legacy HIV organization that started during the 70s. [4:35] What is the definition of long-term HIV survivor? [5:35] Just living and surviving is not enough. We must look back, reflect, and address the long-term issues that these marginalized groups are facing.  [7:35]The impact of having to live with HIV and being told you are going to die soon affects anyone's mental health.  [8:15] Derrick talks about his experience at The Reunion Project. There are gaps within the HIV+ community.  [12:10] The Reunion Project helps people who are still struggling. They created town halls that help community members connect with more people.  [14:25] When people come together and share collective stories, it gives people another perspective of life and hope that they are not alone. [16:55] People are hungry for information, it's like an appetizer. The meal is where people come together to build connections with one another.  [19:05] Being able to receive support as well as give support has been vital. [20:40] Long-time survivors are often silent about their experience and what they are feeling or going through.  [23:35] The trauma of an HIV diagnosis today is likely not at the same level as survivors who have lived with this disease for more than 20 years.  [25:55] How do we expand and keep being responsive to the community that we are committed to? [26:45] In California, the governor is signing the HIV and AGING act. What does this mean for the community?    RESOURCES:  https://www.tpan.com/reunion-project Shanti.org Tpan.com  Jeff Berry on Twitter Derrick Mapp on LinkedIn The Reunion Project on Twitter The Reunion Project on Facebook Email info@reunionproject.net    QUOTES:  “Anyone who has self-identified as a longtime survivor is in fact a long-time survivor.” “People are hungry for information, it's almost like an appetizer that opens to the meal. The meal is the connection that people get with one another.“ “The wounded healers are out there doing the work but are also a part of the work.”

Hey Bookshelvers! Hope this podcast finds you all well. Here we are back for our first book review show since our mini hiatus and we couldn't be more excited to clue you in to what we think is a wonderful, powerful life changing book. When Dogs Heal by Jesse Freidin, Dr Robert Garofalo, Christina Garofalo and Zach Stafford have created and curated a wonderful, vital and life affirming work of art that is as world view changing as it is beautiful. Powerful stories and photographs of people living with HIV and the dogs who saved them.All the books we have reviewed on Barks From have made us think and grow but possibly none more than this. We are also thrilled and humbled to talk to Jesse and Robert all about this wonderful book.Delve deep and enjoyLink to When Dogs Heal Website https://www.whendogsheal.org/Link to Donate to Fred Sayshttps://www.whendogsheal.org/fred-saysLink to the PACT websitehttps://www.pact-dogs.comLink to our Patreon page to help support us make the show!https://www.patreon.com/BookshelversLink to Steve & Corrins Goodall Dog Training Facebook pagehttps://www.facebook.com/goodalldogs/Link to Nat's Training & Behaviour Facebook pagehttps://www.facebook.com/Natdogs/Link to Drax's Galactic Adventure Facebook page (Nat's rescued Irish Wolfhound)https://www.facebook.com/Draxthewolfhound/Link to Steve & Sallys Childrens book 'Jack & Billy Puppy Tales'https://www.facebook.com/JackandBillyPuppyTales/Link to Grant Sharkey's Spotify page (Grant's amazing song 'Grow' features each week as our outro tune.https://open.spotify.com/artist/13PaCwwgVR77TbJH6XAVHQ?si=EOQGmWdCRCiXdECNmJvNAQn

Patients infected with HIV have a higher chance of dying from COVID-19 by 30%, according to a new study from the World Health Organization. HIV-positive patients are also more likely to become severely ill from COVID, and more likely to die if hospitalized with the virus.

My Brother's Keeper, Inc. (MBK) is a private, nonprofit, 501(c) (3) organization with three offices in the Jackson, MS metropolitan area, (headquarters in Ridgeland) and two offices in South Mississippi – Hattiesburg and Gulfport. MBK's mission is to reduce health disparities throughout the United States by enhancing the health and well-being of minority and marginalized populations through leadership in public and community health practices, collaboration, and partnerships. Learn more about MBK at, https://mbkinc.org/about-us/ Southern Charm: Cedric Sturdevant is the executive director of Community Health-PIER, which is a new CBO in the Mississippi Delta, whose mission “is to create a platform for rural communities to decrease the vicious cycle of health disparities through education, intervention, and research.” Cedric is an advocate for HIV, working with and training HIV-positive people to be an advocate for themselves and others through a program called AIDSWatch Mississippi. In 2019, Cedric partnered with NASTAD on Ending the HIV Epidemics –  https://www.nastad.org/blog/leading-through-epidemics

Join this expert discussion regarding the stigma of living with HIV. Credit available for this activity expires: 4/6/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/948521?src=mkm_podcast_addon_948521

#DidYouKnow: Prevention of Tuberculosis in People Living with HIV requires prevention interventions for both HIV infection and TB. This includes HIV counseling, testing, disclosure, partner testing and behavior modification to mention a few. Rumbidzai Venge speaks to Dr. Rachel Weber, HIV Services Branch Chief, CDC Zimbabwe and Dr. Blessing Mushangwe, Senior Program Manager, Zim-TTECH. Follow the conversation as they discuss preventing TB among people living with HIV in Zimbabwe. Courtesy of The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)

For more information on RAHMA, go to http://haverahma.org/. For more information on Sister Reach, visit https://www.sisterreach.org/.

Optimizing Long-Term Care for People Living With HIV: Patient and Treatment Considerations

Current Affairs programme which provides listeners with the latest local and International news hosted by Elvis Preslin. Tune in 104-107 every Saturday and Sunday morning from 6 to 7 am

This one is noooo snoozer. Is Steff a downer? Why was Julia bullied for having a driver's license? The team opens with some classic trivia before this week's discussion on U=U, PEP and PrEP. Did you know that people living with HIV can have unprotected sex if they're following the proper treatment protocol? Learn all about this and more on this week's installment of Pozcast. Tune in weekly and don't forget to follow us:IG: @thepozcastTwitter: @thepozcast_Facebook: Hello PozcastEmail: hellopozcast@gmail.comIntro Music: “Inspirational Outlook” by scottholmesmusic.com 

Support the Informer Daily, Donate to JOY A recent study published in PLOS ONE looked into the attitudes of 30,000 Australians living with HIV regarding clinical research into a cure... LEARN MORE The post New research into people living with HIV and clinical trials appeared first on The Informer.

Support the Informer Daily, Donate to JOY A recent study published in PLOS ONE looked into the attitudes of 30,000 Australians living with HIV regarding clinical research into a cure... LEARN MORE The post New research into people living with HIV and clinical trials appeared first on The Informer.

Tonight we have COVID-19 updates for the LGBTI community. We have updates from the Federal Government, State Government and some specialist advice for people living with HIV. We talk to... LEARN MORE The post COVID-19 Updates for people living with HIV, how do you keep essential services going, and more appeared first on The Informer.

Tonight we have COVID-19 updates for the LGBTI community. We have updates from the Federal Government, State Government and some specialist advice for people living with HIV. We talk to... LEARN MORE The post COVID-19 Updates for people living with HIV, how do you keep essential services going, and more appeared first on The Informer.

Show Notes: On episode 113 we welcome Nina Martinez, the first person living with HIV to become a lifesaver through living donation. Learn how this remarkable medical milestone came to fruition. Then TGL podcast veteran, Dr. Christine Durand, joins us for an update on how the HOPE Act has changed the landscape for those waiting on a second chance at life through organ donation. We learn tips about practicing gratitude, share a resource for using preferred language to address people living with HIV and honor hero Randy Parent on this episode of The Gifted Life Podcast.

Nina Putnis and Alice Zwerling (University of Ottawa, Canada) discuss the potential of a simple urine-based TB screening process for people living with TB and HIV.

The Smithsonian National Museum of Natural History in Washington DC has honored it's first South African Aids Activist for her work. An exhibition of Yvette Alta Raphael in the fight against HIV/Aids was launched yesterday. Raphael is a trusted globally renown advocate on effective and efficient education to the general community regarding new and developing research for medications that treat and/or prevent HIV. She co-found the Tshwaranang Care Center for People Living With HIV & AIDS (PLWHA) and speaks around the globe to advise researchers, advocates, and policy makers. Tsepiso Makwetla spoke to Yvette Raphael